Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours.

Chung P, O'Malley ME, Jewett MAS, Bedard PL, Panzarella T, Sturgeon J, Moore MJ, Hamilton R, Hansen AR, Anson-Cartwright L, Gospodarowicz M, Warde P.

Eur Urol Oncol. 2019 Jul;2(4):437-442. doi: 10.1016/j.euo.2018.08.031. Epub 2018 Oct 2.

PMID:
31277780
2.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Jun 18. pii: S0302-2838(19)30455-5. doi: 10.1016/j.eururo.2019.06.006. [Epub ahead of print]

PMID:
31227307
3.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Jun 19:JCO1900107. doi: 10.1200/JCO.19.00107. [Epub ahead of print]

PMID:
31216227
4.

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA.

Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786. No abstract available.

5.

Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option.

Hamilton RJ, Jewett MAS, Warde P, Hansen A.

Eur Urol Focus. 2019 May 22. pii: S2405-4569(19)30138-5. doi: 10.1016/j.euf.2019.05.003. [Epub ahead of print]

PMID:
31129064
6.

Role of Active Surveillance for Localized Small Renal Masses.

Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, Volpe A, Jewett MAS, Kutikov A, Pierorazio PM; Young Academic Urologists Kidney Cancer working group of the European Urological Association.

Eur Urol Oncol. 2018 Aug;1(3):177-187. doi: 10.1016/j.euo.2018.05.001. Epub 2018 May 26. Review.

PMID:
31102618
7.

Long-term oncological outcomes of patients with paratesticular sarcoma.

Goldberg H, Wong LM, Dickson B, Catton C, Yap SA, Alkasab T, Evans A, van der Kwast T, Jewett MAS, Hamilton RJ.

BJU Int. 2019 Apr 18. doi: 10.1111/bju.14775. [Epub ahead of print]

PMID:
31001920
8.

Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.

Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, Chung P, Warde P, Sweet J, O'Malley M, Sturgeon J, Jewett MAS.

J Clin Oncol. 2019 Feb 25:JCO1801250. doi: 10.1200/JCO.18.01250. [Epub ahead of print]

PMID:
30802156
9.

Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases.

Prendeville S, Richard PO, Jewett MAS, Kachura JR, Sweet JM, van der Kwast TH, Cheung CC, Finelli A, Evans AJ.

J Clin Pathol. 2019 May;72(5):363-367. doi: 10.1136/jclinpath-2018-205655. Epub 2019 Feb 12.

PMID:
30755496
10.

Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors.

Lewin J, Dufort P, Halankar J, O'Malley M, Jewett MAS, Hamilton RJ, Gupta A, Lorenzo A, Traubici J, Nayan M, Leão R, Warde P, Chung P, Anson Cartwright L, Sweet J, Hansen AR, Metser U, Bedard PL.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.18.00004.

11.

Germ Cell Testicular Tumors-Contemporary Diagnosis, Staging and Management of Localized and Advanced disease.

Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N, Hamilton RJ, Jewett MAS.

Urology. 2019 Mar;125:8-19. doi: 10.1016/j.urology.2018.12.025. Epub 2018 Dec 28. Review.

PMID:
30597167
12.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
13.

Classification tree for the prediction of malignant disease and the prediction of non-diagnostic biopsies in patients with small renal masses.

Organ M, MacDonald LP, Jewett MAS, Ajzenberg H, Almatar A, Abdolell M, Acker MR, Rendon R.

Can Urol Assoc J. 2019 Apr;13(4):115-119. doi: 10.5489/cuaj.5196. Epub 2018 Sep 27.

14.

Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management.

Herrera-Caceres JO, Finelli A, Jewett MAS.

World J Urol. 2019 Mar;37(3):437-443. doi: 10.1007/s00345-018-2373-9. Epub 2018 Jul 18.

PMID:
30022406
15.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
16.

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

17.

Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses.

Nayan M, Jewett MAS, Finelli A.

JAMA Intern Med. 2018 May 1;178(5):727-728. doi: 10.1001/jamainternmed.2018.1180. No abstract available.

PMID:
29801131
18.

Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.

Lewin J, Soltan Ghoraie L, Bedard PL, Hamilton RJ, Chung P, Moore M, Jewett MAS, Anson-Cartwright L, Virtanen C, Winegarden N, Tsao J, Warde P, Sweet J, Haibe-Kains B, Hansen AR.

BJU Int. 2018 Nov;122(5):814-822. doi: 10.1111/bju.14372. Epub 2018 May 31.

PMID:
29726090
19.

Roles for active surveillance in renal cancer.

Herrera-Caceres JO, Jewett MAS.

Curr Opin Urol. 2018 Jul;28(4):375-382. doi: 10.1097/MOU.0000000000000506.

PMID:
29697471
20.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
21.

Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses.

Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A.

Can Urol Assoc J. 2018 Aug;12(8):260-266. doi: 10.5489/cuaj.5065. Epub 2018 Apr 6.

22.

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ.

J Urol. 2018 Jul;200(1):126-135. doi: 10.1016/j.juro.2018.02.068. Epub 2018 Feb 21.

PMID:
29474847
23.

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.

PMID:
29428550
24.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.

25.

Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Lieng H, Warde P, Bedard P, Hamilton RJ, Hansen AR, Jewett MAS, O'malley M, Sweet J, Chung P.

Can Urol Assoc J. 2018 Feb;12(2):59-66. doi: 10.5489/cuaj.4531. Epub 2017 Dec 1. Review.

26.

The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians.

Jones J, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa N, Basiuk J, Canil C, Al-Asaaed S, Heng D, Wood L, Stacey D, Kollmannsberger C, Jewett MAS.

Can Urol Assoc J. 2017 Dec;11(12):379-387. doi: 10.5489/cuaj.4590. Epub 2017 Nov 1.

27.

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L, Chung PW, Warde PR, Moore MJ, Bedard PL, Tran B.

Clin Genitourin Cancer. 2017 Sep 4. pii: S1558-7673(17)30267-7. doi: 10.1016/j.clgc.2017.08.012. [Epub ahead of print]

PMID:
28943331
28.

Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance.

Chandrasekar T, Ahmad AE, Fadaak K, Jhaveri K, Bhatt JR, Jewett MAS, Finelli A.

J Urol. 2018 Mar;199(3):633-640. doi: 10.1016/j.juro.2017.09.078. Epub 2017 Sep 20.

PMID:
28941915
29.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

30.

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7.

PMID:
28779441
31.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

32.

Setting Research Priorities for Kidney Cancer.

Jones JM, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa NS, Basiuk J, Canil C, Al-Asaaed S, Heng DYC, Wood L, Stacey D, Kollmannsberger C, Jewett MAS.

Eur Urol. 2017 Dec;72(6):861-864. doi: 10.1016/j.eururo.2017.04.011. Epub 2017 May 8.

PMID:
28495043
33.

An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B.

Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.

34.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

35.

CUA guideline on the management of cystic renal lesions.

Richard PO, Violette PD, Jewett MA, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E66-E73. doi: 10.5489/cuaj.4484. Epub 2017 Mar 16. No abstract available.

36.

28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed robotically.

Hayes JR, Jewett MA, Hamilton RJ.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E257-E260. doi: 10.5489/cuaj.3492. Epub 2016 Jul 12.

37.

Structured assessment and followup for patients with hereditary kidney tumour syndromes.

Lattouf JB, Pautler SE, Reaume MN, Kim RH, Care M, Green J, So A, Violette PD, Saliba I, Major P, Silver S, Leicht R, Basiuk J, Tanguay S, Jewett MA, Drachenberg D; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E214-E222. doi: 10.5489/cuaj.3798. Epub 2016 Jul 12. Erratum in: Can Urol Assoc J. 2017 Aug;11(8):E325.

38.

Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P.

J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1141.

PMID:
28095147
39.

MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with T 1, T 2 and ADC.

McGrath DM, Lee J, Foltz WD, Samavati N, van der Kwast T, Jewett MA, Chung P, Ménard C, Brock KK.

Phys Med Biol. 2017 Feb 7;62(3):1126-1148. doi: 10.1088/1361-6560/aa52f4.

40.

Outcomes after Radical Nephrectomy for Renal Cell Carcinoma.

Jewett MA.

J Urol. 2017 Feb;197(2S):S114-S115. doi: 10.1016/j.juro.2016.11.088. Epub 2016 Dec 20. No abstract available.

PMID:
28010970
41.

Diabetes and kidney cancer outcomes: a propensity score analysis.

Nayan M, Finelli A, Jewett MA, Juurlink DN, Austin PC, Kulkarni GS, Hamilton RJ.

Endocrine. 2017 Feb;55(2):470-477. doi: 10.1007/s12020-016-1149-5. Epub 2016 Nov 4.

PMID:
27815768
42.

Surveillance of Small Renal Masses.

Ahmad AE, Finelli A, Jewett MAS.

Urology. 2016 Dec;98:8-13. doi: 10.1016/j.urology.2016.06.005. Epub 2016 Jul 7. Review.

PMID:
27397098
43.

Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be Reclassified.

Bhatt JR, Jewett MA, Richard PO, Kawaguchi S, Timilshina N, Evans A, Alibhai S, Finelli A.

J Urol. 2016 Nov;196(5):1350-1355. doi: 10.1016/j.juro.2016.05.118. Epub 2016 Jun 21.

PMID:
27341751
44.

The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours.

Nayan M, Jewett MA, Anson-Cartwright L, Bedard PL, Moore M, Chung P, Warde P, Sweet J, O'Malley M, Hamilton RJ.

Can Urol Assoc J. 2016 May-Jun;10(5-6):204-209.

45.

Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry.

Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A.

BJU Int. 2017 Apr;119(4):543-549. doi: 10.1111/bju.13630. Epub 2016 Sep 7.

46.

Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.

Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ.

Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12.

PMID:
27527805
47.

Re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403-6.

Richard PO, Jewett MA, Finelli A.

Eur Urol. 2017 Feb;71(2):e45-e46. doi: 10.1016/j.eururo.2016.07.010. Epub 2016 Aug 6. No abstract available.

PMID:
27506950
48.

Statin use and kidney cancer outcomes: A propensity score analysis.

Nayan M, Finelli A, Jewett MAS, Juurlink DN, Austin PC, Kulkarni GS, Hamilton RJ.

Urol Oncol. 2016 Nov;34(11):487.e1-487.e6. doi: 10.1016/j.urolonc.2016.06.007. Epub 2016 Jul 15.

PMID:
27427224
49.

Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis.

Nayan M, Finelli A, Jewett MA, Juurlink DN, Austin PC, Kulkarni GS, Hamilton RJ.

Clin Genitourin Cancer. 2017 Apr;15(2):300-305. doi: 10.1016/j.clgc.2016.06.008. Epub 2016 Jun 23.

PMID:
27424258
50.

Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.

Lobo NC, Gedye C, Apostoli AJ, Brown KR, Paterson J, Stickle N, Robinette M, Fleshner N, Hamilton RJ, Kulkarni G, Zlotta A, Evans A, Finelli A, Moffat J, Jewett MA, Ailles L.

BMC Cancer. 2016 Jul 16;16:485. doi: 10.1186/s12885-016-2539-z.

Supplemental Content

Loading ...
Support Center